Key Quantitative Figures
- Total Amount to be Raised: ₹20.05 crores
- Amount Already Raised: ₹12.69 crores received from investors against conversion of 63,44,000 share warrants
- Additional Amount Received: ₹1.84 crores received against 36,81,000 share warrants
- Working Capital Utilization: ₹8.37 crores utilized till June 30, 2026
- General Corporate Purpose Utilization: ₹0.20 crores utilized till June 30, 2026
Entities Involved
- Listed Entity: Venmax Drugs and Pharmaceuticals Limited
- Stock Exchange: BSE Limited
- Regulatory Reference: SEBI Listing Regulations, Regulation 32
Fund Utilization Objects
1. Working Capital: ₹10 crores allocated, ₹8.37 crores utilized as of June 30, 2026
2. General Corporate Purpose and Business Acquisition: ₹10.05 crores allocated, ₹0.20 crores utilized as of June 30, 2026
Compliance Status
- Deviation/Variation: No deviation or variation in use of funds
- Monitoring Agency: Not applicable
- Auditor Comments: Nil
- Audit Committee Comments: Reviewed and confirmed compliance in meeting held on August 7, 2026
Additional Details
- Company CIN: L24230TG1988PLC009102
- GSTIN: 36AAACY1073C3ZM